Naperiglipron clinical trials
Also written LY3549492.
How each study uses naperiglipron is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the naperiglipron studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- LY3549492
- 10
Studies by the year they started
10 studies that test it; most in 2025 (5)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 0
Often tested with
Tested in the same studies.
Atorvastatin (1) · Midazolam (1) · Mazdutide (1) · Eloralintide (1) · Macupatide (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test naperiglipron.
- Sep 2027A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightPhase 2 · Eli Lilly and Company
Studies
Open first, then newest update. How each study uses naperiglipron is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightRecruitingPhase 2Eli Lilly and CompanyNCT06143956Written as LY3549492
- A Study of LY3549492 in Healthy Participants and Participants With Overweight or ObesityCompletedPhase 1Eli Lilly and CompanyNCT07232732Written as LY3549492
- A Study of LY3549492 in Healthy Weight Adult ParticipantsTerminatedPhase 2Eli Lilly and CompanyNCT07085468Written as LY3549492
- A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 DiabetesTerminatedPhase 2Eli Lilly and CompanyNCT07030868Written as LY3549492
- A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or OverweightCompletedPhase 2Eli Lilly and CompanyNCT06683508Written as LY3549492
- A Study of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus (T2D) and Healthy Japanese ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT06869018Written as LY3549492
- A Study of LY3549492 in Chinese Participants With Type 2 Diabetes MellitusCompletedPhase 1Eli Lilly and CompanyNCT07073170Written as LY3549492
- A Study of LY3549492 in Participants With Type 2 Diabetes Mellitus (T2DM)CompletedPhase 1Eli Lilly and CompanyNCT05327595Written as LY3549492
- A Study of Carbon-14-Labeled [14C]-LY3549492 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT06194500Written as [14C]-LY3549492
- A Study of LY3549492 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT04758234Written as LY3549492
Codes
What other systems call naperiglipron · ClinicalTrials.gg INT016111
- UNII (FDA) BJN78TT46SNAPERIGLIPRONOne source FDA
- NCI Thesaurus C223294NaperiglipronOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | BJN78TT46S | NAPERIGLIPRON | One source FDA |
| NCI Thesaurus | C223294 | Naperiglipron | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.